MARKET

LLY

LLY

Lilly
NYSE

Real-time Quotes | Nasdaq Last Sale

144.75
-0.15
-0.10%
After Hours: 144.10 -0.65 -0.45% 19:36 11/25 EST
OPEN
144.90
PREV CLOSE
144.90
HIGH
145.34
LOW
142.61
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
170.75
52 WEEK LOW
115.92
MARKET CAP
138.47B
P/E (TTM)
23.70
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Zacks · 6h ago
Merck Sales Hit Hardest by Pandemic
Revenue expected to decline more than 3%, while GlaxoSmithKline projected to gain more than 2%
GuruFocus.com · 1d ago
Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020. Michael Mason, Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a virtual fireside chat at 2:40 p.m., Eastern Time.
PR Newswire · 2d ago
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Zacks · 2d ago
'Covid-19 antibody treatment wing set up by state at El Paso Convention Center makeshift hospital' -ABC KVIA.com Report
https://kvia.com/news/el-paso/2020/11/24/state-establishes-covid-19-antibody-treatment-wing-at-el-paso-convention-center-makeshift-hospital/?fbclid=IwAR1HtBzFbod7l_YTf03XIxDo5mJ7DZ5BBSXdwDbDwktiSmhBL5mvla2Ashs
Benzinga · 2d ago
Should Value Investors Choose Eli Lilly and Co (LLY) Stock?
Let's see if Eli Lilly and Co (LLY) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks · 2d ago
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
Zacks · 2d ago
Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak
(Bloomberg) -- Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 122% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.Regeneron has touted its two-antibody cocktail as being better than single-antibody treatments like those from Lilly or Vir. Yet Scangos, a former Biogen Inc. chieftain, said that while Lilly and Regeneron’s medicines block the ability of the virus to infect cells, the virus could evade these antibodies by mutating.‘Babe Ruth’“Would you rather have two random baseball players or Babe Ruth?,” he said. “It’s not just the number but the quality and the characteristics of the antibody.”Vir’s antibody was developed not from a Covid-19 patient but from one who’d recovered from severe acute respiratory syndrome, or SARS, which is also caused by a coronavirus. The company chose an antibody that also works against Covid-19 and Scangos postulates that it responds to something in the SARS and Covid viruses that hasn’t changed over years of viral evolution.He also sees potential advantage for Vir’s antibody in its engagement of part of the immune system where Lilly and Regeneron’s molecules have had less potent activity.Baird’s Madhu Kumar, the only analyst with a sell-equivalent rating on Vir, is skeptical. He said this particular component of Lilly and Regeneron’s antibodies may be what led to some safety signals and “could trigger inflammatory cascades that could be detrimental to patients.” This particularly concerns hospitalized patients, which Vir is still studying, Kumar told Bloomberg.Email requests for comment to Lilly and Regeneron weren’t returned.Much of Kumar’s skepticism is tied to Vir’s valuation. Even after the stock pulled way back from a Feb. 27 record, it’s still has more than doubled this year. He’s also wary of the market for antibodies in general because successful vaccine results from Pfizer Inc. and partner BioNTech SE as well as Moderna Inc. have blunted its longer term “tail value.”Outside of Covid-19, Kumar has a positive view on Vir. “There’s a real company behind this,” he said, calling out Vir’s hepatitis B RNAi platform.Others on Wall Street take a more optimistic view with five analysts deeming it a buy, and one with a hold rating. The average analyst price target of $55 suggests the Street expects shares may almost double over the next 12 months.GlaxoSmithKline Plc is also a believer and has invested $250 million in San Francisco-based Vir. The duo are in a deal to pursue not only Covid-19 but future coronaviruses using CRISPR screening technology and artificial intelligence to find new compounds.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LLY. Analyze the recent business situations of Lilly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LLY stock price target is 165.88 with a high estimate of 200.00 and a low estimate of 142.00.
EPS
Institutional Holdings
Institutions: 2.24K
Institutional Holdings: 769.15M
% Owned: 80.41%
Shares Outstanding: 956.58M
TypeInstitutionsShares
Increased
606
21.24M
New
240
2.55M
Decreased
646
31.64M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Ricks
Chief Financial Officer/Senior Vice President
Joshua Smiley
Senior Vice President/Chief Information Officer
Aarti Shah
Senior Vice President/Chief Scientific Officer
Daniel Skovronsky
Senior Vice President/Chief Compliance Officer
Melissa Barnes
Senior Vice President/General Counsel
Anat Hakim
Senior Vice President/Director of Human Resources
Stephen Fry
Senior Vice President
Patrik Jonsson
Senior Vice President
Michael Mason
Senior Vice President
Johna Norton
Senior Vice President
Myles O'Neill
Senior Vice President
Leigh Pusey
Senior Vice President
Anne White
Senior Vice President
Ilya Yuffa
Senior Vice President
Alfonso Zulueta
Independent Director
Ralph Alvarez
Lead Director/Independent Director
Juan Luciano
Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn Bertozzi
Independent Director
Michael Eskew
Independent Director
J. Erik Fyrwald
Independent Director
Jamere Jackson
Independent Director
William Kaelin
Independent Director
Marschall Runge
Independent Director
Kathi Seifert
Independent Director
Jackson Tai
Independent Director
Karen Walker
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/19/2020
Dividend USD 0.74
11/12/2020
07/15/2020
Dividend USD 0.74
08/13/2020
05/04/2020
Dividend USD 0.74
05/14/2020
12/16/2019
Dividend USD 0.74
02/13/2020
10/21/2019
Dividend USD 0.645
11/14/2019
06/19/2019
Dividend USD 0.645
08/14/2019
05/06/2019
Dividend USD 0.645
05/16/2019
12/19/2018
Dividend USD 0.645
02/14/2019
10/15/2018
Dividend USD 0.563
11/14/2018
06/18/2018
Dividend USD 0.563
08/14/2018
05/07/2018
Dividend USD 0.563
05/16/2018
12/11/2017
Dividend USD 0.563
02/14/2018
10/16/2017
Dividend USD 0.52
11/14/2017
06/19/2017
Dividend USD 0.52
08/11/2017
05/01/2017
Dividend USD 0.52
05/11/2017
12/13/2016
Dividend USD 0.52
02/13/2017
10/18/2016
Dividend USD 0.51
11/10/2016
06/20/2016
Dividend USD 0.51
08/11/2016
05/02/2016
Dividend USD 0.51
05/11/2016
12/08/2015
Dividend USD 0.51
02/10/2016
10/19/2015
Dividend USD 0.5
11/10/2015
06/15/2015
Dividend USD 0.5
08/12/2015
05/04/2015
Dividend USD 0.5
05/14/2015
12/15/2014
Dividend USD 0.5
02/11/2015
10/20/2014
Dividend USD 0.49
11/12/2014
06/16/2014
Dividend USD 0.49
08/13/2014
05/05/2014
Dividend USD 0.49
05/13/2014
12/16/2013
Dividend USD 0.49
02/12/2014
10/21/2013
Dividend USD 0.49
11/13/2013
06/18/2013
Dividend USD 0.49
08/13/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LLY
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eli Lilly And Co stock information, including NYSE:LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.